Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-3068 plus toripalimab in advanced solid tumors
CTR20210091Phase 2Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JAB-3068, toripalimab in Nonhematologic neoplasms, Esophageal Squamous Cell Carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), sponsored by Jacobio Pharmaceuticals. Started Jan 2021; status: completed.
02
Drugs
JAB-3068toripalimab
03
Conditions
Nonhematologic neoplasmsEsophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210091.